News und Analysen
LivaNova to Host Conference Call for Third Quarter 2021 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its third quarter 2021 results on Wednesday, November 3, 2021 at 12
LivaNova to Present at the Baird 2021 Global Healthcare Conference
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present at the Baird 2021 Global Healthcare
LivaNova Announces Early Retirement of $450 Million Term Loan and Executes $125 Million Revolving Credit Facility
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the early retirement of its $450 million five-year senior secured term loan (the Term Loan)
LivaNova Prices Offering of Ordinary Shares
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that it has priced an underwritten offering of 3,636,364 ordinary shares at a price to the
LivaNova Announces Offering of Ordinary Shares
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has commenced an underwritten offering of $300 million of its ordinary shares. LivaNova
LivaNova Reports Second Quarter 2021 Results and Appoints Alex Shvartsburg as Chief Financial Officer
LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2021.
For the second quarter of 2021, worldwide
LivaNova to Host Conference Call for Second Quarter 2021 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second quarter 2021 results on Wednesday, July 28, 2021 at 1 p.m
Genus plc to Hold Capital Markets Event Today at 10:00 AM ET and Provide Update on its Porcine PRRSv Resistance Program
Genus plc (LSE: GNS), a leading global animal genetics company, is hosting a Capital Markets Event (CME) today at 10 AM ET, 3pm UK time. The CME will cover key strategic progress and initiatives
LivaNova Receives FDA Approval for Clinical Study to Evaluate the aura6000 System to Treat Obstructive Sleep Apnea
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to proceed with its
LivaNova vollzieht den initialen Verkaufsabschluss des Herzklappengeschäfts an Gyrus Capital
LivaNova PLC (NASDAQ:LIVN), ein marktführendes Unternehmen im Bereich Medizintechnik und Innovation, gab heute bekannt, dass es den initialen Abschluss der Veräußerung seines Herzklappengeschäfts
LivaNova Completes Initial Closing of Heart Valve Business to Gyrus Capital
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has successfully completed the initial closing of the divestiture of its heart valve (HV)
LivaNova to Present at the UBS Global Healthcare Virtual Conference
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present at the UBS Global Healthcare Virtual
LivaNova Reports First Quarter 2021 Results
LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2021.
For the first quarter of 2021, worldwide
LivaNova and Verily Announce First Patient Enrolled in Study to Evaluate Treatment Effectiveness for Patients Living with Depression
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, and Verily, a subsidiary of Alphabet focused on life sciences and healthcare, today announced that the first
LivaNova Receives FDA 510(k) Clearance for B-Capta, the New In-Line, Blood-Gas Monitoring System Integrated Into the S5 Heart-Lung Machine
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for B-Capta®, the new
LivaNova Achieves Clinical Milestone in Heart Failure Program
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has randomized the 300th patient in the Autonomic Regulation Therapy to Enhance Myocardial
LivaNova to Host Conference Call for First Quarter 2021 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first quarter 2021 results on Wednesday, April 28, 2021 at 12 p.m
Genus plc Reports Interim First Half 2021 Fiscal Year Results
Genus plc (LSE: GNS), a global biotechnology leader in animal genetics, today reported interim results for the six-months period ending December 31, 2020, as well as provided a business update on
LivaNova Reports Fourth Quarter and Full-Year 2020 Results
LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2020.
For the fourth quarter of
LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth quarter and full-year 2020 results on Wednesday, February
Genus plc Provides Update on Financial Performance for First Half of Fiscal 2021
Genus plc (LSE: GNS), a global biotechnology leader in animal genetics, today reported continued strong performance across its operations for the six-months period ending December 31, 2020.
The
LivaNova Announces Board Appointment and Board Leadership Changes
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a series of enhancements to the Company’s governance.
Todd Schermerhorn has been appointed
LivaNova und Gyrus Capital schließen Vereinbarung über den Kauf des Herzklappengeschäfts
LivaNova PLC (NASDAQ:LIVN), ein marktführendes Medizintechnik- und Innovationsunternehmen, und Gyrus Capital (Gyrus), eine Investmentfirma, die sich auf Investitionen im Gesundheits- und
LivaNova to Host Satellite Symposium on Advances in Neuromodulation at American Epilepsy Society AES2020 Virtual Event
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it will host “Updates and Advances in Neuromodulation,” a satellite symposium at AES2020, the
LivaNova and Gyrus Capital Enter into Agreement for the Purchase of Heart Valve Business
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, and Gyrus Capital (Gyrus), an investment firm dedicated to investments in the healthcare and sustainability